Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1868 results
May 2016
-
Featured News
Fighting high blood pressure in Vietnam
The Novartis Foundation is launching a blood pressure management program in Vietnam as part of its larger effort to combat the rise of chronic diseases in urban areas of developing countries.
-
Press release
Novartis Foundation and partners launch innovative hypertension program in Vietnam
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the… -
Story From Our Labs
Electrical brainstorms traced to genetic mutations
Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.
-
Press release
Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations
FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro… -
Story From Our Labs
Eye disease tracked to a glitch in starburst cells
A cellular computing error wreaks havoc on vision.
-
In The News
Novartis Access perspectives: Fighting Africa's future epidemics
An editorial for the World Economic Forum by Harald Nusser, Head Novartis Access & Malaria Initiative
April 2016
-
Press release
Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional… -
Story Discovery
Collaborating to unlock secrets of the microbiome
Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.
-
Press release
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential… -
Story Patient Perspectives
Patient advocacy at work: one man’s contributions to the COPD community
Read how one caregiver established an association to provide resources for both COPD patients and caregivers.
-
Story Discovery
Talking to: Bruno Strigini on why we're entering a transformative time in cancer care
Accelerating Research to Get Answers Faster
-
Press release
Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…